Clinical Trial Revenue was Longeveron’s largest product and service line in fiscal 2025, bringing in $1.91M of $2.40M (80%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Clinical Trial Revenue | $1.88M | $1.34M | $2.80M | $1.91M |
| Contract Manufacturing Revenue | — | — | $974.00K | $444.00K |
| Contract Manufacturing Lease Revenue | — | — | $1.01M | $46.00K |
| National Institute Of Health - Grant | $328.00K | — | — | — |
| Mscrf – Tedco - Grants | $236.00K | — | — | — |
| National Institutes Of Health – Grant | — | $82.00K | — | — |
| Grant Revenue | — | $82.00K | — | — |
| Total | $2.44M | $1.50M | $4.78M | $2.40M |
Longeveron brought in $2.40M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 49.9% from $4.78M in fiscal 2024. Clinical Trial Revenue was the largest at $1.91M (79.6%), ahead of Contract Manufacturing Revenue at $444.00K (18.5%) and Contract Manufacturing Lease Revenue at $46.00K (1.9%).
Compared with fiscal 2024, Clinical Trial Revenue fell 32.0% to $1.91M and Contract Manufacturing Revenue fell 54.4% to $444.00K.
Longeveron began breaking out Contract Manufacturing Revenue in fiscal 2024 and Contract Manufacturing Lease Revenue in fiscal 2024. Longeveron stopped reporting National Institute Of Health - Grant ($328.00K in fiscal 2022), Mscrf – Tedco - Grants ($236.00K in fiscal 2022), National Institutes Of Health – Grant ($82.00K in fiscal 2023) and one other as separate lines.
Clinical Trial Revenue was Longeveron’s largest revenue line in fiscal 2021, bringing in $1.42M of $2.61M (54%).
| Income Statement Location | FY 2020 | FY 2021 |
|---|---|---|
| Clinical Trial Revenue | — | $1.42M |
| Alzheimer’S Association - Grant | — | $520.00K |
| National Institutes Of Health - Grant | — | $424.00K |
| Mscrf – Tedco - Grant | — | $252.00K |
| Contract Manufacturing Revenue | $110.00K | — |
| Total | $110.00K | $2.61M |
Longeveron brought in $2.61M from its four revenue lines in fiscal 2021, the year ended December 31, 2021. Longeveron regrouped these revenue lines after fiscal 2020, so the total does not compare directly with that year's $110.00K. Clinical Trial Revenue was the largest at $1.42M (54.2%), ahead of Alzheimer’S Association - Grant at $520.00K (19.9%) and National Institutes Of Health - Grant at $424.00K (16.2%). The remaining revenue line, Mscrf – Tedco - Grant, brought in $252.00K.
Longeveron began breaking out Clinical Trial Revenue in fiscal 2021, Alzheimer’S Association - Grant in fiscal 2021, National Institutes Of Health - Grant in fiscal 2021 and Mscrf – Tedco - Grant in fiscal 2021. Longeveron stopped reporting Contract Manufacturing Revenue as a separate revenue line after fiscal 2020, when it brought in $110.00K.
Longeveron (LGVN) reports its revenue by product and service and by income statement location. In fiscal 2025, Clinical Trial Revenue was its largest product and service line, bringing in $1.91M (79.6% of the total), followed by Contract Manufacturing Revenue at $444.00K (18.5%).
Clinical Trial Revenue was Longeveron's largest product and service line in fiscal 2025, bringing in $1.91M, or 79.6% of the $2.40M total across its three product and service lines.
Clinical Trial Revenue was Longeveron's largest revenue line in fiscal 2021, bringing in $1.42M, or 54.2% of the $2.61M total across its four revenue lines.
Every figure comes from Longeveron's annual financial filings, as reported. Each line keeps the name Longeveron gives it, and years follow its fiscal calendar.
Longeveron's revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.